deucravacitinib
bms
[' psa', 'deucra']
#spa #abstracts #acr22 1598. safety and efficacy of deucravacitinib, an oral, selective tyk2 inhibitor, in patients with psa: 52-wk results from a rct ph2 trial efficacy in pasdas + other key efficacy measures, maintained no new safety signals #acrambassador 
Rheumatologist | Epi | ASAS | Twitter Ambassador (ACR/ ARD-BMJ) | ArLAR ARCH President | St Joseph University & HDF Beirut | Love Music | Travel Books